3.5.1.89: N-acetylglucosaminylphosphatidylinositol deacetylase
This is an abbreviated version!
For detailed information about N-acetylglucosaminylphosphatidylinositol deacetylase, go to the full flat file.
Word Map on EC 3.5.1.89
-
3.5.1.89
-
glycosylphosphatidylinositol
-
trypanosomal
-
glcn-pi
-
sickness
-
gpi-anchored
-
de-n-acetylation
-
alpha-mannosyltransferase
-
medicine
-
mannosylated
-
drug development
- 3.5.1.89
- glycosylphosphatidylinositol
-
trypanosomal
-
glcn-pi
- sickness
-
gpi-anchored
-
de-n-acetylation
- alpha-mannosyltransferase
- medicine
-
mannosylated
- drug development
Reaction
Synonyms
2-acetamido-2-deoxy-alpha-D-glucopyranosyl-(1->6)-phosphatidylinositol de-N-acetylase, Acetylglucosaminylphosphatidylinositol deacetylase, alpha-D-GlcpNAc-PI de-N-acetylase, CaGpi12, Deacetylase, acetylglucosaminylphosphatidylinositol, deNAc, EC 3.1.1.69, GlcNAc-phosphatidylinositol deacetylase, GlcNAc-PI de-N-acetylase, GlcNAc-PI deacetylase, GlcNAc-PI-de-N-acetylase, GlcNAc-PI-deacetylase, GPI, GPI12, N-acetyl-D-glucosaminylphosphatidylinositol de-N-acetylase, N-acetylglucosamine-phosphatidylinositolde-N-acetylase, N-acetylglucosaminyl phosphatidylinositol de-N-acetylase, N-Acetylglucosaminylphosphatidylinositol de-N-acetylase, N-acetylglucosaminylphosphatidylinositol deacetylase, PIG-L, PIG-L protein, TbGPI12
ECTree
3.5.1.89 N-acetylglucosaminylphosphatidylinositol deacetylaseAdvanced search results
results (
results (Inhibitors
Inhibitors on EC 3.5.1.89 - N-acetylglucosaminylphosphatidylinositol deacetylase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
INHIBITOR 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
(1R,2R)-1-O-(2-acetylamino-2-deoxy-alpha-D-glucopyranosyl)-cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate)
-
competitive
(1R,2R)-1-O-(2-acetylamino-2-deoxy-beta-D-glucopyranosyl)-cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate)
-
-
(1R,2R)-1-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl)-cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate)
-
-
(1R,2R)-1-O-(2-amino-2-deoxy-beta-D-glucopyranosyl)-cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate)
-
-
(1R,2R)-2-((2-deoxy-2-[(hydroxycarbamoyl)amino]-beta-D-glucopyranosyl)oxy)cyclohexyl octadecyl phosphate
-
-
(1R,2R)-2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)oxy]cyclohexyl octadecyl phosphate
-
-
(1R,2R)-2-[(2-acetylamino-2-deoxy-alpha-D-glucopyranosyl)oxy]cyclohexyl octadecyl phosphate
-
-
(1R,2R)-2-[(2-amino-2-deoxy-alpha-D-glucopyranosyl)oxy]cyclohexyl octadecyl phosphate
-
-
(1R,2R)-2-[(2-amino-2-deoxy-beta-D-glucopyranosyl)oxy]cyclohexyl octadecyl phosphate
-
-
(1R,2R,3S,4R,5R,6R)-2-([2-deoxy-2-[(hydroxycarbamoyl)amino]-alpha-D-glucopyranosyl]oxy)-3,4,5,6-tetrahydroxycyclohexyl octadecyl hydrogen phosphate
-
-
(1R,2S,3R,4R,5R)-4-(prop-2-en-1-yl)-6,8-dioxabicyclo[3.2.1]octane-2,3-diyl diacetate
-
-
(2R)-3-{[{[(1R,2R,3S,4R,5R,6R)-2-{[2-(carbamoylamino)-2-deoxy-alpha-D-glucopyranosyl]oxy}-3,4,5,6-tetrahydroxycyclohexyl]oxy}(hydroxy)phosphoryl]oxy}propane-1,2-diyl dihexadecanoate
-
-
1,3,4,6-tetra-O-acetyl-2-C-carboxymethyl-2-deoxy-alpha-D-glucopyranose
-
-
1,5-anhydro-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-3-O-phenyl-D-glucitol
-
-
1,5-anhydro-3-O-benzyl-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-D-glucitol
-
-
1,5-anhydro-3-O-benzyl-4,6-O-benzylidene-2-(carboxymethyl)-2-deoxy-D-glucitol
-
-
1,5-anhydro-3-O-benzyl-4,6-O-benzylidene-2-[2-[(benzyloxy)amino]-2-oxoethyl]-2-deoxy-D-glucitol
-
-
1,5-anhydro-4,6-O-benzylidene-2-[2-[(benzyloxy)amino]-2-oxoethyl]-2-deoxy-D-glucitol
-
-
1-acetyl-N-[4-hydroxy-3-(hydroxycarbamoyl)phenyl]piperidine-4-carboxamide
-
40% inhibition at 1 mM
1-{1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}-2-hydroxyethan-1-one
-
-
2-deoxy-2-ureido-D-galactosylalpha1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol
-
suicide inhibitor, 50% inihibition at 0.0002 mM
2-deoxy-2-ureido-D-glucosyl-alpha1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol
2-deoxy-2-ureido-D-glucosyl-beta1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol
-
50% inhibition at about 8 nM
2-deoxy-2-ureido-D-glucosylalpha1-6-D-(2-O-octyl)myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol
-
50% inhibition at about 8 nM
2-deoxy-2-ureido-D-glucosylbeta1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol
-
suicide inhibitor, 50% inihibition at 0.0002 mM
5-[(cyclohexanecarbonyl)amino]-N,2-dihydroxybenzamide
-
99% inhibition at 1 mM
EDTA
complete inhibition at 10 mM, the enzyme irreversibly loses activity upon incubation with a metal chelator
ethambutol
docking study, the effective enzyme inhibitor may be useful in the treatment of African sleeping sickness
metaraminol
docking study, the effective enzyme inhibitor may be useful in the treatment of African sleeping sickness
N,N-diethylethanaminium (1R,2R)-2-(2-acetamido-3-hydroxypropoxy)cyclohexyl octadecyl phosphate
-
-
N,N-diethylethanaminium 1-D-2-[(2-acetamido-2-deoxy-alpha-D-glucopyranosyl)oxy]-myo-inosityl octadecyl phosphate
-
-
N-((1R,2R)-2-[(2-acetamido-2-deoxy-alpha-D-glucopyranosyl)oxy]cyclohexyl)octadecane-1-sulfonamide
-
-
N-((1R,2R)-2-[(2-acetamido-2-deoxy-beta-D-glucopyranosyl)oxy]cyclohexyl)octadecane-1-sulfonamide
-
-
N-(1R,2R)-2-O-(2-amino-2-deoxy-alpha-D-glucopyranosyl)-cyclohexyloctadecane-1-sulphonamide
-
-
N-(1R,2R)-2-O-(2-amino-2-deoxy-beta-D-glucopyranosyl)-cyclohexyloctadecane-1-sulphonamide
-
-
N-dimethyl-D-glucosyl-phosphatidylinositol
-
0.001 mM, complete inhibition
N-[4-hydroxy-3-(hydroxycarbamoyl)phenyl]-2H-1,3-benzodioxole-5-carboxamide
-
86% inhibition at 1 mM
N-[4-hydroxy-3-(hydroxycarbamoyl)phenyl]oxane-4-carboxamide
-
56% inhibition at 1 mM
N-[4-hydroxy-3-(hydroxycarbamoyl)phenyl][1,1'-biphenyl]-4-carboxamide
-
75% inhibition at 1 mM
phenyl 3,4,6-tri-O-acetyl-2-C-allyl-2-deoxy-1-thio-alpha-D-glucopyranoside
-
-
phenyl 3,4,6-tri-O-acetyl-2-C-allyl-2-deoxy-1-thio-beta-D-glucopyranoside
-
-
phenyl 3,4,6-tri-O-acetyl-2-C-carboxymethyl-2-deoxy-1-thio-alpha-D-glucopyranoside
-
-
phenyl 3,4,6-tri-O-acetyl-2-C-carboxymethyl-2-deoxy-1-thio-beta-D-glucopyranoside
-
-
phenyl 3,4,6-tri-O-acetyl-2-deoxy-2-C-formylmethyl-1-thio-alpha-D-glucopyranoside
-
-
phenyl 3,4,6-tri-O-acetyl-2-deoxy-2-C-formylmethyl-1-thio-beta-D-glucopyranoside
-
-
salicylic hydroxamic acid
-
enzyme inhibitor with high ligand efficiency, proposed mode of action, overview
triethylammonium 1R,2R-1-O-[2-C-(carboxymethyl N-hydroxyamide)-2-deoxy-beta-D-glucopyranosyl]-cyclohexanediol 2-(n-octadecylphosphate)
-
-
triethylammonium trans-2-(2-amino-3-hydroxypropoxy)-cyclohexyl n-octadecyl phosphate
-
-
2-deoxy-2-ureido-D-glucosyl-alpha1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol
-
50% inhibition between 0.0001 and 0.001 mM
2-deoxy-2-ureido-D-glucosyl-alpha1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol
-
50% inhibition at 8 nM
additional information
-
treatment with EDTA consistently causes up to 2% reduction in activity, the activity is not significantly affected by treatment with 1,10-phenanthroline
-
additional information
-
not inhibitory up to 0.1 mM: 2-deoxy-2-ureido-D-glucosyl-beta1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol, 2-deoxy-2-ureido-D-glucosylalpha1-6-D-(2-O-octyl)myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol
-
additional information
-
inhibitor identification via zinc binding fragment screening, structure activity relationship, hydroxamic acid and 2-OH are essential for potency, substitution is tolerated at the 4- and 5-positions. No inhibition by 2-bromo-N-hydroxybenzamide and 2-amino-N-hydroxybenzamide
-
additional information
-
(1R,2R)-1-O-(2-acetylamino-2-deoxy-beta-D-glucopyranosyl)-cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate) is neither a substrate nor an inhibitor
-
additional information
inhibitor search by structural based virtual screening (SBVS), molecular modeling, and docking study, overview
-
additional information
-
inhibitor search by structural based virtual screening (SBVS), molecular modeling, and docking study, overview
-
